Embetta公司终止了胰岛素补丁泵方案,侧重于核心业务,发现库存激增了33.5%。 Embecta Corp discontinues insulin patch pump program, focuses on core business, sees stock surge 33.5%.

一家糖尿病护理公司Embetta Corp(一家糖尿病护理公司)报告Q4收入丰厚,但宣布计划停止其胰岛素补丁泵方案和结构调整,而是将重点放在核心业务和减债方面。 Embecta Corp, a diabetes care company, reported strong Q4 earnings but announced plans to discontinue its insulin patch pump program and restructure, focusing instead on its core business and debt reduction. 该公司预计将在2025年财政中节省60至6 500万美元,但仍预测收入增长。 The company expects to save $60-$65M in fiscal 2025 and still projects revenue growth. 尽管这个计划中止了 Embeckta的股票 上涨了33.5% 达到19.23美元 Despite the program's discontinuation, Embecta's stock rose 33.5% to $19.23.